Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 14

1.

Influenza and Pneumococcal Vaccination in Hematological Malignancies: a Systematic Review of Efficacy, Effectiveness, and Safety.

La Torre G, Mannocci A, Colamesta V, D'Egidio V, Sestili C, Spadea A.

Mediterr J Hematol Infect Dis. 2016 Sep 1;8(1):e2016044. doi: 10.4084/MJHID.2016.044. Review.

2.

Challenges in the Role of Gammaglobulin Replacement Therapy and Vaccination Strategies for Hematological Malignancy.

Sánchez-Ramón S, Dhalla F, Chapel H.

Front Immunol. 2016 Aug 22;7:317. doi: 10.3389/fimmu.2016.00317. Review.

3.

Infectious diseases in allogeneic haematopoietic stem cell transplantation: prevention and prophylaxis strategy guidelines 2016.

Ullmann AJ, Schmidt-Hieber M, Bertz H, Heinz WJ, Kiehl M, Krüger W, Mousset S, Neuburger S, Neumann S, Penack O, Silling G, Vehreschild JJ, Einsele H, Maschmeyer G; Infectious Diseases Working Party of the German Society for Hematology and Medical Oncology (AGIHO/DGHO) and the DAG-KBT (German Working Group for Blood and Marrow Transplantation)..

Ann Hematol. 2016 Sep;95(9):1435-55. doi: 10.1007/s00277-016-2711-1.

4.

Technical guidelines for the application of seasonal influenza vaccine in China (2014-2015).

Feng L, Yang P, Zhang T, Yang J, Fu C, Qin Y, Zhang Y, Ma C, Liu Z, Wang Q, Zhao G, Yu H.

Hum Vaccin Immunother. 2015;11(8):2077-101. doi: 10.1080/21645515.2015.1027470.

5.

A novel influenza A (H1N1) outbreak experience among residents of a long term-care facility in Saudi Arabia during 2010 seasonal flu circulation.

Affifi RM, Omar SR, El Raggal AA.

Infect Dis Rep. 2012 Mar 13;4(1):e23. doi: 10.4081/idr.2012.e23. Review.

6.

Low seroconversion after one dose of AS03-adjuvanted H1N1 pandemic influenza vaccine in solid-organ transplant recipients.

Resende MR, Husain S, Gubbay J, Singer L, Cole E, Renner EL, Rotstein C.

Can J Infect Dis Med Microbiol. 2013 Spring;24(1):e7-e10.

7.

CD4 T cell help is limiting and selective during the primary B cell response to influenza virus infection.

Alam S, Knowlden ZA, Sangster MY, Sant AJ.

J Virol. 2014 Jan;88(1):314-24. doi: 10.1128/JVI.02077-13.

8.

The effect of rituximab on vaccine responses in patients with immune thrombocytopenia.

Nazi I, Kelton JG, Larché M, Snider DP, Heddle NM, Crowther MA, Cook RJ, Tinmouth AT, Mangel J, Arnold DM.

Blood. 2013 Sep 12;122(11):1946-53. doi: 10.1182/blood-2013-04-494096.

9.

Prevention of infection caused by immunosuppressive drugs in gastroenterology.

Orlicka K, Barnes E, Culver EL.

Ther Adv Chronic Dis. 2013 Jul;4(4):167-85. doi: 10.1177/2040622313485275.

10.

A randomized trial of one versus two doses of influenza vaccine after allogeneic transplantation.

Karras NA, Weeres M, Sessions W, Xu X, Defor T, Young JA, Stefanski H, Brunstein C, Cooley S, Miller JS, Blazar BR, Wagner JE, Verneris MR.

Biol Blood Marrow Transplant. 2013 Jan;19(1):109-16. doi: 10.1016/j.bbmt.2012.08.015.

11.

Vaccination of oncology patients: an effective tool and an opportunity not to be missed.

Kotton CN, Poznansky MC.

Oncologist. 2012;17(1):1-2. doi: 10.1634/theoncologist.2011-0383. No abstract available.

12.

Immunogenicity of an inactivated monovalent 2009 influenza A (H1N1) vaccine in patients who have cancer.

Xu Y, Methuku N, Coimbatore P, Fitzgerald T, Huang Y, Xiao YY, Pagala M, Gupta S, Solomon W, Rubin P, Treanor J, Astrow A, Minkoff H, Cooper JS.

Oncologist. 2012;17(1):125-34. doi: 10.1634/theoncologist.2011-0220.

13.

Influenza vaccination for immunocompromised patients: systematic review and meta-analysis from a public health policy perspective.

Beck CR, McKenzie BC, Hashim AB, Harris RC, Zanuzdana A, Agboado G, Orton E, Béchard-Evans L, Morgan G, Stevenson C, Weston R, Mukaigawara M, Enstone J, Augustine G, Butt M, Kim S, Puleston R, Dabke G, Howard R, O'Boyle J, O'Brien M, Ahyow L, Denness H, Farmer S, Figureroa J, Fisher P, Greaves F, Haroon M, Haroon S, Hird C, Isba R, Ishola DA, Kerac M, Parish V, Roberts J, Rosser J, Theaker S, Wallace D, Wigglesworth N, Lingard L, Vinogradova Y, Horiuchi H, Peñalver J, Nguyen-Van-Tam JS.

PLoS One. 2011;6(12):e29249. doi: 10.1371/journal.pone.0029249. Review.

14.

Graft-versus-host disease is the major determinant of humoral responses to the AS03-adjuvanted influenza A/09/H1N1 vaccine in allogeneic hematopoietic stem cell transplant recipients.

Mohty B, Bel M, Vukicevic M, Nagy M, Levrat E, Meier S, Grillet S, Combescure C, Kaiser L, Chalandon Y, Passweg J, Siegrist CA, Roosnek E; Blood and Marrow Transplant Program.; Geneva University Hospitals H1N1 study group..

Haematologica. 2011 Jun;96(6):896-904. doi: 10.3324/haematol.2011.040386.

Items per page

Supplemental Content

Support Center